Taxus Cardium Pharmaceuticals Group, Inc. (CRXM)
OTC PINK OTC PINK Primary Summary
Taxus Cardium Pharmaceuticals Group, Inc. (CRXM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Taxus Cardium Pharmaceuticals Group, Inc. ever had a stock split?
Taxus Cardium Pharmaceuticals Group, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher J. Reinhard CEO | OTC PINK Exchange | 876767104 CUSIP |
| US Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Gene Biotherapeutics, Inc. is a biotechnology company that operates in the clinical development stage, focusing on innovating and bringing to market angiogenic gene therapy treatments specifically targeting cardiovascular conditions within the United States. The company is primarily engaged in the advancement of its investigational compound, Generx, which is currently in Phase 3 clinical trials. Generx is designed to offer a potential treatment for patients who experience myocardial ischemia and severe, intractable angina due to advanced coronary artery disease. In addition to its primary focus, Gene Biotherapeutics is also delving into the possibilities that Generx may have for other therapeutic applications linked to ischemia, not only within the cardiovascular system but also extending to cerebral implications. To support the production of Generx during these critical Phase 3 evaluations, Gene Biotherapeutics has formed a strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies. Established in 2003, the company is headquartered in San Diego, California, and officially rebranded to Gene Biotherapeutics, Inc. in January 2018, having previously operated under the name Taxus Cardium Pharmaceuticals Group, Inc.
Products and Services
- Generx
Generx is an investigational angiogenic gene therapy candidate that aims to provide a revolutionary treatment for patients experiencing myocardial ischemia and severe angina that do not respond to conventional therapies. Currently undergoing Phase 3 clinical trials, Generx aims to stimulate the growth of new blood vessels, potentially improving blood flow to the heart and alleviating debilitating symptoms of coronary artery disease.
- Clinical Development and Research
As a company firmly rooted in research and development, Gene Biotherapeutics is dedicated to advancing the understanding and application of angiogenic gene therapy. Their focus on clinical trials ensures that they are on the cutting edge of scientific innovation in treating cardiovascular conditions, thereby contributing to the overall improvements in patient outcomes.
- Manufacturing Partnerships
To ensure the successful production of their products, particularly Generx, Gene Biotherapeutics has entered into a manufacturing partnership with Fujifilm Diosynth Biotechnologies. This collaboration facilitates the efficient and effective manufacturing of their angiogenic gene therapy, ensuring high-quality standards are met throughout the clinical development process.
- Exploration of Therapeutic Applications
Beyond its primary focus on cardiovascular conditions, Gene Biotherapeutics is actively exploring the potential uses of Generx in treating ischemia across various organ systems, including cerebral applications. This commitment to broader therapeutic exploration exemplifies the company's dedication to enhancing treatment options for conditions related to ischemia.
